Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma ...
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...
cio.economictimes.indiatimes23 天
BCG report unveils GenAI’s untapped potential to reinvent India’s ITeS industry
India’s IT enabled services industry is at a defining crossroads. According to Boston Consulting Group’s (BCG) latest report, "The GenAI Adoption Conundrum," Generative AI (GenAI) isn’t just ...
brandequity.economictimes.indiatimes24 天
India's Retail sector set for explosive growth: BCG-RAI Report
The Retail Kaleidoscope," released by the Boston Consulting Group (BCG) and the Retailers Association of India (RAI) at the Retail Leadership Summit 2025. The report highlights India's robust ...